NO933971L - Leveringssystem med kontrollert for-lenget frigivelse for roeykeopp hoer - Google Patents

Leveringssystem med kontrollert for-lenget frigivelse for roeykeopp hoer

Info

Publication number
NO933971L
NO933971L NO933971A NO933971A NO933971L NO 933971 L NO933971 L NO 933971L NO 933971 A NO933971 A NO 933971A NO 933971 A NO933971 A NO 933971A NO 933971 L NO933971 L NO 933971L
Authority
NO
Norway
Prior art keywords
lobelin
delivery system
smoke
drug delivery
individual
Prior art date
Application number
NO933971A
Other languages
English (en)
Other versions
NO933971D0 (no
Inventor
Judith A Kitchell
Indu A Muni
Yvonne N Boyer
Original Assignee
Dynagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynagen Inc filed Critical Dynagen Inc
Publication of NO933971D0 publication Critical patent/NO933971D0/no
Publication of NO933971L publication Critical patent/NO933971L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Det beskrives et medikamentleveringssystem som er nyttig for å hjelpe individer i å slutte å røyke eller tygge nikotinholdige produkter. Leveringssystemet omfatter et fysisk tvunget moduleringssystem (PCMS) inneholdende lobelin. Medikament-leveringssystemet er i stand til å levere lobelin til et individ på en kontrollert, forlenget frigivende måte og tilveiebringer langstids terapeutiske mengder lobelin til individet. Leveringen av lobelin på en slik måte reduserer eller eliminerer individets røyke- eller tyggevaner. PCMS kan være en biologisk nedbrytbar polymer inneholdende lobelinet som kan injiseres subkutant eller intramuskulært eller implanteres inn i individet, eller kan være del av et trans-dermalt plaster inneholdende lobelin. Det beskrives også fremgangsmåter for anvendelse av medikamentleveringssystemene og sett inneholdende medikamentleveringssystemene.
NO933971A 1991-05-07 1993-11-03 Leveringssystem med kontrollert for-lenget frigivelse for roeykeopp hoer NO933971L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69663791A 1991-05-07 1991-05-07
PCT/US1992/003860 WO1992019241A1 (en) 1991-05-07 1992-05-07 A controlled, sustained release delivery system for smoking cessation

Publications (2)

Publication Number Publication Date
NO933971D0 NO933971D0 (no) 1993-11-03
NO933971L true NO933971L (no) 1994-01-07

Family

ID=24797928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933971A NO933971L (no) 1991-05-07 1993-11-03 Leveringssystem med kontrollert for-lenget frigivelse for roeykeopp hoer

Country Status (8)

Country Link
EP (1) EP0720478A1 (no)
JP (1) JPH06507416A (no)
AU (2) AU2154892A (no)
CA (1) CA2102507A1 (no)
FI (1) FI934919A (no)
HU (1) HUT69390A (no)
NO (1) NO933971L (no)
WO (2) WO1992019226A1 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
ZA932273B (en) * 1992-03-30 1993-11-26 Alza Corp Additives for bioerodible polymers to regulate degradation
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5612357A (en) * 1992-05-18 1997-03-18 Pharmaco Behavioral Associates, Inc. Use of cotinine to assist in the cessation of tobacco smoking
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
SE519940C2 (sv) * 1994-06-03 2003-04-29 Carl Dahlborn Ab Implanterbar anordning
ATE214276T1 (de) * 1994-09-19 2002-03-15 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AU748804B2 (en) * 1995-07-20 2002-06-13 Smithkline Beecham Plc Paroxetine controlled release compositions
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
AU3601897A (en) * 1996-07-15 1998-02-09 Alza Corporation Novel formulations for the administration of fluoxetine
EP1393724B1 (en) * 1996-07-15 2006-04-05 Alza Corporation Novel formulations for the transdermal administration of fluoxetine
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830904A (en) * 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
WO1998053815A1 (en) * 1997-05-30 1998-12-03 Minnesota Mining And Manufacturing Company Transdermal drug delivery device for the delivery of tropisetron or granisetron
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
ES2141024B1 (es) * 1997-10-03 2000-10-16 Manzanares Jesus Mari Gonzalez Preparado de accion antinicotinica.
DE19746191C2 (de) 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
CA2318738A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
CA2318921A1 (en) 1998-01-29 1999-08-05 John R. Mccullough Pharmacological uses of optically pure (+)-bupropion
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
ATE531374T1 (de) 2004-04-15 2011-11-15 Alkermes Inc Vorrichtung auf polymerbasis mit verzögerter freisetzung
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4917676A (en) * 1986-11-20 1990-04-17 Ciba-Geigy Corporation User-activated transdermal therapeutic system
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
CA1273878A (en) * 1987-01-15 1990-09-11 Richard Philip Moody Nicotine-containing preparation for transdermal administration
JP2677371B2 (ja) * 1988-01-30 1997-11-17 帝國製薬株式会社 含水性喫煙代用貼付剤
EP0432945A1 (en) * 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction

Also Published As

Publication number Publication date
JPH06507416A (ja) 1994-08-25
FI934919A0 (fi) 1993-11-05
HUT69390A (en) 1995-09-28
WO1992019226A1 (en) 1992-11-12
AU2016092A (en) 1992-12-21
AU657973B2 (en) 1995-03-30
FI934919A (fi) 1993-12-17
WO1992019241A1 (en) 1992-11-12
NO933971D0 (no) 1993-11-03
CA2102507A1 (en) 1992-11-08
EP0720478A1 (en) 1996-07-10
AU2154892A (en) 1992-12-21
HU9303146D0 (en) 1994-01-28

Similar Documents

Publication Publication Date Title
NO933971L (no) Leveringssystem med kontrollert for-lenget frigivelse for roeykeopp hoer
NO923769D0 (no) System for iontoforetisk tilfoersel av et medikament
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
AU2740595A (en) Transdermal drug delivery system
MX9602656A (es) Dispositivo transdermico que contiene pirrolidona polivinilica como mejorador de solubilidad.
GR3029308T3 (en) Medical device for the administration of active ingredients or drugs at very low doses, particularly homeopathic drugs.
DE69220808D1 (de) Vorrichtung zur verabreichung von heilmitteln
CA2260750A1 (en) Methods for providing safe local anesthesia
ATE415941T1 (de) Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
NO20026171L (no) Topiske farmasöytiske formuleringer og fremgangsmåter for behandling
ATE370764T1 (de) Vorrichtung zur lokalen verabreichung von fest- oder halbfesten pharmazeutischen zusammensetzungen
AU1099288A (en) Drug delivery system and method of making the same
HUP0201907A2 (hu) Időzített kettős hatóanyag-leadású dózisformák, amelyek rövid ideig ható altatót vagy annak sóját tartalmazzák
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
DK0946151T3 (da) Doseringsform med stigende dosisfrigivelse
NO993385D0 (no) Transdermalt terapeutisk system for avgivelse av hormoner
ATE228374T1 (de) Arzneiverabreichungssystem
EP0297535A3 (en) Drug delivery devices
Knobil The wisdom of the body revisited
MY107420A (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances.
Garry et al. Diurnal administration of human growth hormone-releasing factor does not modify sleep and sleep-related growth hormone secretion in normal young men
James San Francisco area: testosterone replacement study, injection vs. patch
SIMMONS et al. Postfracture linear bone growth in rats: a diurnal rhythm.
SE9904424D0 (sv) Use of interleukin-6 in combination with leptin in treatment of obesity
SE9802555D0 (sv) New pharmaceutical preparation and method